Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on July 31, 2025

Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

WESTBROOK, Maine, July 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it plans to release financial results for the second quarter ended …

Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the second …

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close …

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and anatomic control Phase 3 dose (3E10 vg …

Stryker reports second quarter 2025 operating results

Stryker reports second quarter 2025 operating results

Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025: Second Quarter Results Reported net sales increased 11.1% to $6.0 billion Organic net sales increased 10.2% Reported …

Safety Shot Appoints Markita Russell as Chief Financial Officer

Safety Shot Appoints Markita Russell as Chief Financial Officer

SCOTTSDALE, AZ, July 31, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced the appointment of Markita L. Russell as its new Chief Financial Officer. Ms. Russell, who has served as the Company's …

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19% Operating cash flow of $539 million Quarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. …

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: …

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome

Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical …

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven …

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on …

CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025

CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025

- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial …

Orchestra BioMed Announces Proposed Public Offering

Orchestra BioMed Announces Proposed Public Offering

NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced …

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement  • Medtronic to invest $10 million in an equity private placement and an …

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial …

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2025 at 4:30 pm ET …

Solésence Reports Second Quarter 2025 Financial Results

Solésence Reports Second Quarter 2025 Financial Results

ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, …

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le …

Half-Year Review of Inventiva’s Liquidity Contract with  Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions